



18 August 2025

Strategic Placement Raises A\$5.0 Million To Accelerate development of dorsaVi's RRAM and Robotics technology

Funding received to support development of next-gen RRAM sensor systems and expansion into edge AI and robotics enabled applications

Key Highlights:

- Firm commitments received to raise \$5 million (before costs) via a Placement to a restricted group of high-net-worth investors at \$0.04 per Share.
- Strong demand received from both new and existing sophisticated and professional investors following recent securing of the exclusive worldwide RRAM licence.
- Proceeds will accelerate development and integration of dorsaVi's RRAM-enabled sensor architecture, video-based AI platforms, and additional complementary innovations.
- Strengthened balance sheet enables dorsaVi to accelerate global growth across sensors, RRAM systems, and robotics initiatives, including its Reflex platform currently under evaluation.

Melbourne, Australia, 18 August 2025: dorsaVi Limited (ASX: DVL) ('dorsaVi' or 'the Company'), a leader in FDA cleared movement-sensor technology, is pleased to announce that it has, over the weekend, received firm commitments to raise \$5.0 million (before costs) through a placement of 125,000,000 fully paid ordinary shares ("New Shares") at an issue price of \$0.04 per share, from new and existing sophisticated, professional, and high net worth investors ("Placement").

The Placement was driven by significant inbound interest from both existing and new investors, following dorsaVi's strategic milestone in securing the exclusive worldwide license to cutting edge RRAM technology¹.

Recent announcements highlighting successful internal testing of RRAM integrated biomedical sensors² demonstrating system level improvements in latency and power efficiency, and the early stage evaluation of its reflex platform designed for next generation robotics and human-machine interfaces³ has generated strong investor enthusiasm around dorsaVi's expansion into high growth technology verticals.

¹ Refer to ASX announcement dated 12 June 2025

² Refer to ASX announcement dated 22 July 2025

³ Refer to ASX announcement dated 04 August 2025

The Placement ensures dorsaVi is well-capitalised to accelerate the development and integration of dorsaVi's RRAM enabled architecture across FDA-cleared sensors, video-based AI, and emerging robotics initiatives.

The Reflex platform, in particular, is being positioned to unlock sub-millisecond reaction times and ultra-low power operation which is a critical enabler for next-generation robotics, exosuits, and neuromorphic systems. Initial validation efforts have shown promising results, with further performance data and commercial exploration expected in due course.

Gernot Abl, Chairman of dorsaVi, commented: "We're thrilled by the overwhelming response to this Placement, which we view as a powerful vote of confidence in dorsaVi's bold new trajectory. The interest we've attracted since securing the exclusive worldwide RRAM licence has confirmed what we already believed, this technology is transformational. RRAM is not just an incremental improvement to our FDA-approved sensor platform, it's a leap into the future of robotics, edge AI, and neuromorphic computing. With this funding, we're now positioned to fast-track multiple high-impact initiatives across human-machine interaction, autonomous robotics, and in-sensor intelligence. Investors can expect a steady stream of milestones as we execute across commercial, technical, and global scaling fronts."

Use of Proceeds

Funds raised from the Placement will be strategically allocated towards the development of DVL's RRAM and sensor technologies, review of additional complementary innovations, and working capital. Additional funds will support working capital to drive operational growth and cover the costs associated with the Placement.

These investments are expected to substantially accelerate dorsaVi's commercialisation roadmap across its existing and new divisions and capitalise on significant growth opportunities in edge computing, artificial intelligence, and innovations in robotics.

Details of the Placement

Under the Placement the Company will issue a total of 125,000,000 Shares at an issue price of \$0.04 per under the Company's existing ASX Listing Rule 7.1 and 7.1A placement capacities. In addition, 62,500,000 free attaching Unlisted Options, on a 1 for 2 basis, with an exercise price of \$0.075 and expiring 3 years from the date of issue, will be issued subject to shareholder approval.

The offer price of \$0.04 per new share represents a:

- 13% discount to the last traded price of \$0.046 per share on 15 August 2025, being the last date that the Company's shares traded on the ASX prior to the date of this announcement;
- 10.4% premium to the 10-day VWAP of \$0.036 per share up to and including 15 August 2025; and
- 17% premium to the 15-Day VWAP of \$0.033 per share up to and including 15 August 2025.

The Placement was led by 62 Capital and Evolution Capital acted as Co-Manager. The Managers will receive a fee of 6% of the gross amount raised, together with 20,000,000 unlisted options exercisable at \$0.075 per option on or before the date that is 3 years from the date the options are issued for services provided as managers. Broker options will be subject to shareholder approval.

The Placement will be completed within dorsaVi's existing ASX Listing Rule 7.1 (utilising 70 million Shares) and 7.1A placement (utilising 55 million Shares) capacities. Settlement of the New Shares is expected to occur on or around 29 August 2025.

This announcement has been authorised for release by the Board of Directors.

For further information about dorsaVi, please contact:

Gernot Abl Chairman +61 419 802 653 Email: ga@dorsaVi.com	Andrew Ronchi Chief Executive Officer +61 417 882 267 Email: ar@dorsaVi.com
--	--

About dorsaVi

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Boeing, Monash Health, Coles, Woolworths, Toll, Toyota, Orora, Mineral Resources and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove+) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into physical therapy (physiotherapists), hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refer to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance.

Further information is available at www.dorsaVi.com